Classification of anticancer drugs—a new system based on therapeutic targets

This publication has 72 references indexed in Scilit:

• Antisense therapy for cancer—the time of truth
  The Lancet Oncology, 2002
• High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas
  Zeitschrift für Krebsforschung und Klinische Onkologie, 2002
• Gleevec™ for the Treatment of Chronic Myelogenous Leukemia: U.S. Food and Drug Administration Regulatory Mechanisms, Accelerated Approval, and Orphan Drug Status
  The Oncologist, 2002
• Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer
  International Journal of Clinical Oncology, 2002
• DNA and its associated processes as targets for cancer therapy
  Nature Reviews Cancer, 2002
• Trastuzumab
  Drugs, 2002
• Bisphosphonates for cancer patients: why, how, and when?
  Supportive Care in Cancer, 2001
• The EGFR as a target for anticancer therapy—focus on cetuximab
  European Journal Of Cancer, 2001
• Increased Sensitivity to Cisplatin in Gastric Cancer by Antisense Inhibition of the HER-2/neu (c-erbB-2) Gene
  Chemotherapy, 2001
• Carboxyamido-Triazole (CAI)-a Novel “static” Signal Transduction Inhibitor Induces Apoptosis in Human B-Cell Chronic Lymphocytic Leukemia Cells
  Leukemia & Lymphoma, 2001